Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 263

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 263
---
 |     | $ |     193,750 |     | $ | -         |     | $ | -         |     | $ | (107,638      | ) |     | $ |      86,112 |

| (1) | On                                                                                                                                      
 October 30, 2024, the Company subscribed for 80,000 shares and 240,000 warrants (“Polyrizon Warrants”) of Polyrizon Ltd.                
 (“Polyrizon”) in Polyrizon’s initial public offering on the Nasdaq at a cost of $350,400. Each Polyrizon Warrant can                    
 be exercised into one ordinary share of Polyrizon at an exercise price of $4.38 per share. The Polyrizon Warrants expire on October 29, 
 2029. The fair value of the Polyrizon Warrants as of October 31, 2024, was $178,988 based on the Block-Scholes option pricing model,    
 using the following assumptions: risk-free rate of 4.28%, expected life of 5 years and volatility of 92%. See note 19a.                 |

| (2) | Pursuant                                                                                                                     
 to the Share Exchange Agreement with Xylo Technologies Ltd. (formerly known as Medigus Ltd.) (“Xylo”), on February 14, 2022, 
 the Company received 27,778 ordinary shares of Xylo. The investment cost of the share was $501,938.                          |

During the year ended October 31, 2024, the Company sold all its remaining shares of Xylo, for total proceeds of $ 78,500and recorded changes in fair value of $ 7,612.

F-20 CLEARMIND MEDICINE INC. Notes to the Consolidated Financial Statements (Expressed in United States Dollars)

| 6. | Related            
 Party Transactions |

| a. | Compensation to key management 
 personnel                      |

| (i) | The compensation to key management personnel for employment services they provide to the Company is as follows: |

|                           |     |  Year ended |         |     |  Year ended |         |     |  Year ended |           |
|:--------------------------|:----|------------:|--------:|:----|------------:|--------:|:----|------------:|----------:|
|                           |     | October 31, |         |     | October 31, |         |     | October